BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced today the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Ms. Gorrell brings over two decades of experience advising healthcare organizations on regulatory, governance, and growth initiatives.
In her new role, Ms. Gorrell will oversee BioStem's legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through the company's compliance framework. Her appointment comes as BioStem implements its next phase of growth and progresses toward a Nasdaq uplisting.
“Katherine is a key addition to BioStem as we implement our next phase of growth,” said Jason Matuszewski, Chairman and CEO of BioStem Technologies. “Katherine brings a demonstrated ability to partner effectively with boards and executive teams, and her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting.”
Most recently, Ms. Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, FL, where she was a member of the Executive Team and led legal strategy across a complex healthcare enterprise. She previously served as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services.
Ms. Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah. “BioStem is at a pivotal time in its growth and evolution,” said Gorrell. “I look forward to working with the leadership team and board to support sustainable growth, strengthen governance, and ensure our legal, compliance, and medical affairs functions continue to evolve with the business.”
BioStem Technologies leverages its proprietary BioRetain®, CryoTek® and SteriTek® processing technologies to optimize preservation of natural tissue properties. The company's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes. Its product lines include Neox®, Clarix®, VENDAJE® and American Amnion™.
For more information, visit the company's website at www.biostemtechnologies.com or follow updates in the company's newsroom at https://tinyurl.com/bsemnewsroom.
